Related Experiment Video

Updated: Jun 5, 2026

Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish
07:50

Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish

Published on: July 16, 2012

The development of anti-inflammatory drugs for infectious diseases

Cristiana Couto Garcia1, Rodrigo Guabiraba, Frederico Marianetti Soriani

  • 1Laboratório de Imunofarmacologia, Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais, 31270-901, Brazil.

Discovery Medicine
|December 30, 2010
PubMed

Insights

Disease often stems from inflammation, not just infection. Understanding harmful inflammation mechanisms can lead to new therapies for conditions like influenza, dengue, and sepsis.

Area of Science:

  • Immunology
  • Pathology
  • Infectious Diseases

Background:

  • Traditionally, disease following infection is attributed to the host's insufficient response, allowing pathogen replication.
  • However, infection does not always cause disease; the host's inflammatory response can be the primary driver of tissue damage and mortality.
  • This review challenges the traditional view, proposing a distinction between host defense mechanisms and detrimental inflammation.

Purpose of the Study:

  • To differentiate between host response mechanisms essential for controlling infection and those causing detrimental inflammation leading to disease.
  • To explore how understanding disease-driving mechanisms can inform the development of novel therapeutic strategies.
  • To examine specific examples of influenza, dengue, and sepsis where excessive or aberrant inflammation causes disease.

Main Methods:

  • Review of existing literature on host-pathogen interactions and inflammatory responses.
  • Analysis of three case studies: influenza, dengue, and sepsis.
  • Identification of molecular mediators of disease that are not critical for pathogen clearance.

Main Results:

  • Inflammation, rather than pathogen replication alone, is frequently the direct cause of tissue damage and disease in infections.
  • Unwanted inflammation (excessive, misplaced, or altered) plays a critical role in disease pathogenesis.
  • Specific molecular players driving disease in influenza, dengue, and sepsis have been identified, which are not essential for controlling the respective infections.

Conclusions:

  • Separating essential host defense mechanisms from disease-driving inflammatory processes is crucial.
  • Targeting specific molecules that promote detrimental inflammation, while sparing those vital for infection control, offers a promising therapeutic avenue.
  • Further research into these mechanisms can lead to innovative treatments to alleviate patient suffering from infectious diseases.

More Related Videos

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells06:57

Development of an Antigen-driven Colitis Model to Study Presentation of Antigens by Antigen Presenting Cells to T Cells

Published on: September 18, 2016

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response12:50

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...